The value of cerebrospinal fluid α‐synuclein and the tau/α‐synuclein ratio for diagnosis of neurodegenerative disorders with Lewy pathology
Open Access
- 24 July 2019
- journal article
- research article
- Published by Wiley in European Journal of Neurology
- Vol. 27 (1), 43-50
- https://doi.org/10.1111/ene.14032
Abstract
Background and purpose Parkinson's disease (PD), dementia with Lewy bodies (DLB) and Alzheimer's disease (AD) are three of the most common neurodegenerative disorders. Up to 20% of these patients have the wrong diagnosis, due to overlapping symptoms and shared pathologies. A cerebrospinal fluid (CSF) biomarker panel for AD is making its way into the clinic, but an equivalent panel for PD and DLB and for improved differential diagnoses is still lacking. Using well-defined, community-based cohorts and validated analytical methods, the diagnostic value of CSF total-alpha-synuclein (t-alpha-syn) alone and in combination with total tau (t-tau) in newly diagnosed patients with PD, DLB and AD was determined. Methods Cerebrospinal fluid concentrations of t-alpha-syn were assessed using our validated in-house enzyme-linked immunosorbent assay in 78 PD patients, 20 AD patients, 19 DLB patients and 32 controls. t-tau was measured using a commercial assay. Diagnostic performance was assessed by receiver operating characteristic curve analysis. Results Compared to controls (mean 517 pg/ml), significantly lower levels of CSF t-alpha-syn in patients with PD (434 pg/ml, 16% reduction, P = 0.036), DLB (398 pg/ml, 23% reduction, P = 0.009) and AD (383 pg/ml, 26% reduction, P = 0.014) were found. t-alpha-syn levels did not differ significantly between PD, DLB and AD. The t-tau/t-alpha-syn ratio showed an improved performance compared to the single markers. Conclusion This is the first study to compare patients with PD, DLB and AD at the time of diagnosis. It was found that t-alpha-syn can contribute as a teammate with tau in a CSF biomarker panel for PD and DLB, and strengthen the existing biomarker panel for AD.Funding Information
- Helse Vest Regionalt Helseføretak (911218, 911832, 911698)
This publication has 30 references indexed in Scilit:
- The diagnostic utility of cerebrospinal fluid alpha-synuclein analysis in dementia with Lewy bodies – A systematic review and meta-analysisParkinsonism & Related Disorders, 2013
- Low CSF Levels of Both α-Synuclein and the α-Synuclein Cleaving Enzyme Neurosin in Patients with SynucleinopathyPLOS ONE, 2013
- α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort studyThe Lancet Neurology, 2011
- Interaction between -Synuclein and Other Proteins in Neurodegenerative DisordersThe Scientific World Journal, 2011
- Incidence of Parkinson's disease in Norway: the Norwegian ParkWest studyJournal of Neurology, Neurosurgery & Psychiatry, 2009
- Cerebrospinal fluid α-synuclein in neurodegenerative disorders—A marker of synapse loss?Neuroscience Letters, 2009
- Synaptic pathology in Alzheimer's disease: a review of ultrastructural studiesNeurobiology of Aging, 2003
- Clinical diagnosis of Alzheimer's diseaseNeurology, 1984
- “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinicianJournal of Psychiatric Research, 1975
- ParkinsonismNeurology, 1967